TRITON and Beyond: New Insights into the Profile of Prasugrel

Prasugrel, a third-generation thienopyridine antiplatelet agent, demonstrated superior efficacy to clopidogrel but with an increased risk of bleeding in the phase III pivotal registration Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel–Thrombolysi...

Descripción completa

Detalles Bibliográficos
Autores principales: Jakubowski, Joseph A, Riesmeyer, Jeffrey S, Close, Sandra L, Leishman, Amy G, Erlinge, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2012
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3440581/
https://www.ncbi.nlm.nih.gov/pubmed/21883999
http://dx.doi.org/10.1111/j.1755-5922.2011.00263.x
Descripción
Sumario:Prasugrel, a third-generation thienopyridine antiplatelet agent, demonstrated superior efficacy to clopidogrel but with an increased risk of bleeding in the phase III pivotal registration Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel–Thrombolysis in Myocardial Infarction (TRITON-TIMI 38). This article reviews and discusses select components of a large literature of prasugrel data that has emerged since the TRITON-TIMI 38 (TRITON) study primary disclosure.

Ejemplares similares